KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer

Molecular Biology Reports

Volumn 38, Issue 2, 2011, Pages 1315-1320

  Herreros Villanueva, Marta ^a   Rodrigo, Maximiliano ^a   Claver, Manuel ^a   Muñiz, Pilar ^b   Lastra, Enrique ^a   García Girón, Carlos ^a   Coma Del Corral, Maria Jesus ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b UNIVERSITY OF BURGOS   (Spain)

Author keywords

BRAF; Colorectal cancer; EGFR; HER2; KRAS; Mutation

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; COLORECTAL CANCER; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SPAIN;

EID: 79951578834     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0232-x     Document Type: Article

References (33)

1. A Jemal, et al. 2003 Cancer statistics CA Cancer J Clin 53 1 5 26 10.3322/canjclin.53.1.5 12568441
2. AP Venook 2005 Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma Cancer 103 12 2435 2446 1:CAS:528: DC%2BD2MXlvVCktL4%3D 10.1002/cncr.21123 15880563 (Pubitemid 40800520)
3. MJ Moore, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 15 1960 1966 1:CAS:528:DC%2BD2sXmvVWmsr0%3D 10.1200/JCO.2006.07.9525 17452677 (Pubitemid 46972777)
4. E Van Cutsem, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 10.1200/JCO.2006.08.1620 17470858 (Pubitemid 46797944)
5. NE Hynes HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 5 341 354 1:CAS:528:DC%2BD2MXjslertb0%3D 10.1038/nrc1609 15864276 (Pubitemid 40637826)
6. J Mendelsohn J Baselga 2006 Epidermal growth factor receptor targeting in cancer Semin Oncol 33 4 369 385 1:CAS:528:DC%2BD28XpsVersLk%3D 10.1053/j.seminoncol.2006.04.003 16890793 (Pubitemid 44142736)
7. J Downward 2003 Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 1 11 22 1:CAS:528:DC%2BD38XpvVertbo%3D 10.1038/nrc969 12509763 (Pubitemid 37328883)
8. M Malumbres M Barbacid 2003 RAS oncogenes: the first 30 years Nat Rev Cancer 3 6 459 465 1:CAS:528:DC%2BD3sXktFOnsbs%3D 10.1038/nrc1097 12778136 (Pubitemid 37328850)
9. S Schubbert K Shannon G Bollag 2007 Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 4 295 308 1:CAS:528:DC%2BD2sXjtlyhtLs%3D 10.1038/nrc2109 17384584 (Pubitemid 46480970)
10. HJ Andreyev, et al. 2001 Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 5 692 696 1:CAS:528:DC%2BD3MXns1yktr8%3D 10.1054/bjoc.2001.1964 11531254 (Pubitemid 32929467)
11. V Bazan, et al. 2002 Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann Oncol 13 9 1438 1446 1:STN:280:DC%2BD38vjvVGisQ%3D%3D 10.1093/annonc/mdf226 12196370
12. S Benvenuti, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 6 2643 2648 1:CAS:528:DC%2BD2sXivV2ns7w%3D 10.1158/0008-5472.CAN-06-4158 17363584 (Pubitemid 46548951)
13. W De Roock, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 3 508 515 10.1093/annonc/mdm496 17998284 (Pubitemid 351325672)
14. F Di Fiore, et al. 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 8 1166 1169 1:CAS:528:DC%2BD2sXkt1Gqsbs%3D 10.1038/sj.bjc.6603685 17375050 (Pubitemid 46625066)
15. A Lievre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 8 3992 3995 1:CAS:528:DC%2BD28XjsFSlsb0%3D 10.1158/0008-5472.CAN-06-0191 16618717
16. R Adams T Maughan 2007 Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer Expert Rev Anticancer Ther 7 4 503 518 1:CAS:528:DC%2BD2sXkt1Wqsr0%3D 10.1586/14737140.7.4.503 17428171 (Pubitemid 46681806)
17. R Nahta, et al. 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 5 269 280 1:CAS:528:DC%2BD28Xltlagtbg%3D 10.1038/ncponc0509 16683005 (Pubitemid 43731112)
18. Y Lu, et al. 2007 Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab Cancer Res 67 17 8240 8247 1:CAS:528: DC%2BD2sXpvFKjurs%3D 10.1158/0008-5472.CAN-07-0589 17804738 (Pubitemid 47395161)
19. D Cunningham, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 337 345 1:CAS:528:DC%2BD2cXlvFGitbk%3D 10.1056/NEJMoa033025 15269313 (Pubitemid 38944402)
20. KY Chung, et al. 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 9 1803 1810 1:CAS:528:DC%2BD2MXjt1Ckuro%3D 10.1200/JCO.2005.08.037 15677699 (Pubitemid 46211358)
21. M Moroni, et al. 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 5 279 286 1:CAS:528:DC%2BD2MXjs1Krsb8%3D 10.1016/S1470-2045(05)70102-9 15863375 (Pubitemid 40590264)
22. M Dowsett, et al. 2009 Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial J Clin Oncol 27 18 2962 2969 1:CAS:528:DC%2BD1MXoslyis70%3D 10.1200/JCO.2008.19.7939 19364966
23. JG Paez, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 1497 1500 1:CAS:528:DC%2BD2cXksVGmsbs%3D 10.1126/science.1099314 15118125 (Pubitemid 38720929)
24. CR Newton, et al. 1989 Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17 7 2503 2516 1:CAS:528:DyaL1MXktFyktbs%3D 10.1093/nar/17.7.2503 2785681 (Pubitemid 19103235)
25. N Thelwell, et al. 2000 Mode of action and application of Scorpion primers to mutation detection Nucleic Acids Res 28 19 3752 3761 1:CAS:528:DC%2BD3cXntlKmurk%3D 10.1093/nar/28.19.3752 11000267
26. D Whitcombe, et al. 1999 Detection of PCR products using self-probing amplicons and fluorescence Nat Biotechnol 17 8 804 807 1:CAS:528: DyaK1MXmtFahsr0%3D 10.1038/11751 10429248 (Pubitemid 29365111)
27. S Benlloch, et al. 2006 Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology J Mol Diagn 8 5 540 543 1:CAS:528:DC%2BD28Xhtlagu7zM 10.2353/jmoldx.2006.060070 17065421 (Pubitemid 44774151)
28. RG Amado, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 1626 1634 1:CAS:528:DC%2BD1cXltlWhsrw%3D 10.1200/JCO.2007.14.7116 18316791
29. F Di Nicolantonio, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 35 5705 5712 1:CAS:528:DC%2BD1MXotFemsA%3D%3D 10.1200/JCO.2008.18.0786 19001320
30. DO Kavanagh, et al. 2009 Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9 1 10.1186/1471-2407-9-1 19118499
31. A Ooi, et al. 2004 Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study Mod Pathol 17 8 895 904 1:CAS:528:DC%2BD2cXmvVOltrk%3D 10.1038/modpathol.3800137 15143334 (Pubitemid 38993773)
32. B Schuell, et al. 2006 HER 2/neu protein expression in colorectal cancer BMC Cancer 6 123 1:CAS:528:DC%2BD28XkvV2qtL4%3D 10.1186/1471-2407-6-123 16681853 (Pubitemid 43880548)
33. M Moroni, et al. 2008 EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 9 5 402 403 10.1016/S1470-2045(08)70109-8 18452847 (Pubitemid 351597789)